How profitable is Scholar Rock Holding Corporation (SRRK)?

In FY 2025 (10-K), SRRK converted $1.1B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / SRRK / financials

CGON (42) CRSP (35) IMVT (37) KOD (54) ⌘ Pro Terminal →

Scholar Rock Holding Corporation (SRRK) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$43.98 +2.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $44.09

Scholar Rock Holding Corporation (SRRK) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $5.23B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SRRK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SRRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Scholar Rock Holding Corporation (NASDAQ: SRRK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $43.98 (+2.49% 1D, market cap $5.23B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SRRK ranks #432 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SRRK compare to CGON and CRSP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRRK carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGON (CG Oncology Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B) and CRSP (CRISPR Therapeutics AG) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.6%, cap $4.83B). Among the 5-stock peer group, SRRK leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SRRK?

▼

Per SRRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001727196), Scholar Rock Holding Corporation generated $1.08B in revenue (+52.6% YoY), -$378.0M in net income, and -$300.6M in free cash flow against $404.3M in total assets and $99.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $44.09 (+0.26%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRRK)Realized 20D OHLCV Swing Band: ±7.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY SRRK SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (39% of score)

Altman Z-Score 13.67 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$40.64+3.2% Next Q

Q2 (-2Q)

Grade E$41.96+5.3% Next Q

Q3 (-1Q)

Grade E$44.18-0.5% Next Q

Current

Grade D-$43.98-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRRK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRRK currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($47.31) and Max Pain ($46.18) forces dealer call-delta covering toward $64.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRRK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SRRK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SRRK Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $479.6M

FY24

Rev $705.8M

FY25

Rev $1.08B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.08B	0%	-35.7%	-$378.0M	-$300.6M	-45%
FY 2024	$705.8M	0%	-35.7%	-$246.0M	-$201.0M	-45%
FY 2023	$479.6M	0%	-35.7%	-$166.0M	-$145.2M	-7.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRRK)

✓Walkthrough of SRRK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SRRK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.68%📐 HORIZONTAL RANGE

2026-11-04O $43.90H $43.98L $42.91C $43.98VOL 932.1K

RES: $66.71SUP: $36.83SMA50: $47.31SMA200: $48.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRRK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRRK Butterfly Map → + Track SRRK →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

24.7%/yr Implied 5Y Growth

vs. +52.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SRRK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRRK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SRRK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRRK)

Health Care Rank #432 of 1015 ⚔️ CGON vs SRRK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRRK vs. CGON, CRSP, IMVT, KOD)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Scholar Rock Holding Corporation (SRRK) ranks #432 by composite RQD confidence (41/100, grade D-) and #154 by equity capitalization ($5.23B). Within this direct 5-issuer industry benchmark cohort, SRRK leads on earnings valuation at N/A trailing P/E, while CGON leads on capital efficiency and profitability with -20.8% ROIC and — gross margin. KOD currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with SRRK at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SRRK ACTIVE Scholar Rock Holding Corporation	D-	41/100	—	—	-35.0%	+2.49%	$5.23B	Benchmark Subject
CGON CG Oncology Inc.	D-	42/100	—	—	-20.8%	+3.39%	$5.49B	/cgon-vs-srrk →
CRSP CRISPR Therapeutics AG	D-	35/100	—	—	-30.6%	0.00%	$4.83B	/crsp-vs-srrk →
IMVT Immunovant Inc.	D-	37/100	—	—	-35.0%	+2.22%	$5.87B	/imvt-vs-srrk →
KOD Kodiak Sciences Inc	D+	54/100	—	—	-35.0%	+1.30%	$6.14B	/kod-vs-srrk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001727196 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scholar Rock Holding Corporation (SRRK) reported GAAP revenue of $1.08B (+52.6% vs. FY2024 revenue of $705.8M , and +124.6% cumulative change since FY2023) , GAAP net income of -$378.0M, operating cash flow of -$300.0M, and free cash flow of -$300.6M (-49.5% YoY). On the balance sheet, SRRK closed FY2025 with $404.3M in total assets against $99.7M in total debt (Altman Z-Score: 13.67, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.08B	-$378.0M	-$300.0M	-$300.6M	$404.3M	$99.7M
FY2024 (FY)	2024-12-31	$705.8M	-$246.0M	-$200.9M	-$201.0M	$474.9M	$50.1M
FY2023 (FY)	2023-12-31	$479.6M	-$166.0M	-$145.2M	-$145.2M	$2.96B	$692.5M

3. SRRK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SRRK compare to CGON and CRSP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SRRK?

Where is SRRK trading relative to its 50-day, 200-day, and 52-week technical levels?

SRRK last traded at $43.98 (+2.49% on volume of 676,854 shares), positioning the stock -7.04% below its 50-day simple moving average ($47.31) and -8.70% below its 200-day simple moving average ($48.17). Across its 52-week range of $27.07 to $61.76, SRRK sits at the 48.7% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.5% ($40.68 to $47.28).

Direct Sub-Reports: SRRK RQD Cockpit SRRK 12M Forecast SRRK Earnings & Move SRRK Dividends & DRIP SRRK Insiders & 13F SRRK Whale Options SRRK Profit Sankey SRRK News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SRRK — Scholar Rock Holding Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Scholar Rock Holding Corporation (SRRK) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $43.98 (+2.49% 1D, market capitalization $5.23B).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -5.59%.
Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (16/20): Incorporates a 1.02x equity beta, Altman Z-Score of 13.67, Piotroski F-Score of 5/9, and Debt/Equity of 0.41x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Scholar Rock Holding Corporation (SRRK) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile does not describe its products, customers, or revenue model. The reported revenue in the SEC financials is — for each period shown.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scholar Rock Holding Corporation (SRRK) reported $1.08B in annual revenue (up from $705.8M in FY2024, +52.6% YoY) and -$378.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($479.6M revenue, -$166.0M net income) through FY2025, SRRK scaled operating cash flow to -$300.0M and free cash flow to -$300.6M, backed by $404.3M in total assets against $99.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 41/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -5.59% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $27.07 – $61.76 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.02x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), SRRK carries a macro regime beta of 1.02 and gross margin of —.

Key Question #1: Can SRRK sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.08B and free cash flow of -$300.6M, how will capital allocation balance growth reinvestment against $99.7M in total debt?
Key Question #3: How sensitive is SRRK's 32.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.02x)?

SRRK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scholar Rock Holding Corporation (SRRK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SRRK Debate Forum (3) ↓

🟢 CATALYST Yahoo • 5d ago

Scholar Rock (SRRK) Stock Could Trade At A Premium On Balance Sheet Hopes

Scholar Rock Holding has seen its share price move sharply over recent years, which naturally raises a question for anyone looking at the stock today. Is the current US$44.18 price still grounded in the company’s book va

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12d ago

Scholar Rock Receives FDA's Priority Review Voucher For Isembyld

https://www.federalregister.gov/public-inspection/2026-21718/priority-review-voucher-rare-pediatric-disease-product-isembyld-apitegromab-mstn

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 15d ago

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

CAMBRIDGE, Mass., October 20, 2026--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open.

Read Full Source ↗

🟢 CATALYST Yahoo • 18d ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., October 16, 2026--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly h

Read Full Source ↗

🔴 RISK WATCH Yahoo • 19d ago

EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)

Scholar Rock has resubmitted its Marketing Authorisation Application to the European Medicines Agency for apitegromab in spinal muscular atrophy, switching to an alternate fill-finish facility that already supported the

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 27d ago

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass., October 08, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 32d ago

3 drug targets pharma is betting on next

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 39d ago

Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says

Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SRRK Bull vs. Bear Conversation Board — What's Your Call at $43.98?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRRK 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $53.12 (+21.0%)

📌 Pinned Debate

The forensic balance sheet scores 16/20 with an Altman Z-Score of 13.67 and reported cash rising to $323.5M, giving the company a finan

The forensic balance sheet scores 16/20 with an Altman Z-Score of 13.67 and reported cash rising to $323.5M, giving the company a financial buffer despite operating losses.. When you look under the hood at SRRK, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $61.76. My 12M target is $53.12.

VolSurface_Trader 🐂 BULL

@MultipleCompression Shorting a 7/20 institutional whale-flow stock at $43.90 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $35.12 (-20.0%)

Spot @ $43.90

With ROIC at -35%, FCF of -$300.6M, and EPS (TTM) of -3.1, the company is consuming cash rather than generating it, and reported revenu

With ROIC at -35%, FCF of -$300.6M, and EPS (TTM) of -3.1, the company is consuming cash rather than generating it, and reported revenue is $0.0M.. Look at the math on SRRK: paying 32.0x forward P/E for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $38.63 before getting long.